FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
01/30/2024
Back to search
Official data from USPTO
BARRIOLIDES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
BARRIOLIDES
ST13
US500000079346405Class
1, 5, 42
Filing
79346405
Registration
7178487
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
01/30/2024
Trademark type
Word
Nice classes
1, 5, 42
Filing date
06/09/2022
Registration date
10/03/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/03/2023
Last transaction
10/03/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
78
Owner location
IS
Examiner
KAJUBI, ELIZABETH
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
E. E. (pessoa física)
Representatives
Susan Fentress Veritay Group IP, PLLC
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals used in industryscience and photographyas well as in agriculturehorticulture and forestryexcept fungicidesherbicidesinsecticides and parasiticides; biological preparations for use in industry and science
Class 5
Pharmaceutical and veterinary preparations to improve function of membranes in the body; pharmaceutical and veterinary preparations to improve function of membranes in the lung; pharmaceutical and veterinary preparations to enhance the epithelial barrier; pharmaceutical and veterinary preparations to enhance the airway epithelial barrier; pharmaceutical and veterinary preparations to inhibit inflammation; pharmaceutical and veterinary preparations for the treatment of a disease or condition that is caused by a defect in epithelial cells or tissue; pharmaceutical and veterinary preparations for the treatment of a disease or condition that benefits from enhancement or restoration of epithelial barrier function; pharmaceutical and veterinary preparations for the treatment of a disease or condition of epithelial tissue in the respiratory tract; pharmaceutical and veterinary preparations for the treatment of epithelial dysfunction; pharmaceutical and veterinary preparations for the treatment of human airway epithelial cells; pharmaceutical and veterinary preparations for the treatment of chronic respiratory diseases; pharmaceutical and veterinary preparations for the treatment of viral airways diseases; pharmaceutical and veterinary preparations for the treatment of an airways disease; pharmaceutical and veterinary preparations for the treatment of asthma; pharmaceutical and veterinary preparations for the treatment of chronic obstructive pulmonary disease (COPD); pharmaceutical and veterinary preparations for the treatment of cystic fibrosis; pharmaceutical and veterinary preparations for the treatment of non-cystic fibrosis bronchiectasis; pharmaceutical and veterinary preparations for the treatment of chronic rhinosinusitis; pharmaceutical and veterinary preparations for the treatment of diffuse panbronchiolitis (DPB); pharmaceutical and veterinary preparations for the treatment of chronic bronchitis; pharmaceutical and veterinary preparations for the treatment of bronchiolitis obliterans organizing pneumonia (BOOP); pharmaceutical and veterinary preparations for the treatment of infantile respiratory distress syndrome (IRDS); pharmaceutical and veterinary preparations for the treatment of bronchopulmonary dysplasia; pharmaceutical and veterinary preparations for the treatment of neuromuscular respiratory depression or failure; pharmaceutical and veterinary preparations for the treatment of pneumonia; pharmaceutical and veterinary preparations for the treatment of conditions caused by and associated with respiratory syncytial virus (RSV) and related viruses; pharmaceutical and veterinary preparations for the treatment of a disease or condition commonly associated with inflammation that benefits from enhancement or restoration of epithelial barrier function; pharmaceutical and veterinary preparations for the treatment of systemic inflammatory distress syndrome (SIRS); pharmaceutical and veterinary preparations for the treatment of adult respiratory distress syndrome (ARDS); pharmaceutical and veterinary preparations for the treatment of inflammatory bowel disease; pharmaceutical and veterinary preparations for the treatment of ulcerative colitis; pharmaceutical and veterinary preparations for the treatment of Crohn's disease; sanitary preparations for medical purposes; dietary supplements for human beings and animals
Class 42
Scientific and technological services and research and design relating theretoscientific research in the field of pharmaceutical studies researchscientific research in new pharmaceutical design servicesmedical and pharmacological research servicesdrug discovery servicespharmaceutical drug development servicespharmaceutical research and development; industrial analysis and research servicespharmaceutical analysis and pharmaceutical research
Publications
History of USPTO decisions and trademark events.
29 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/08/2024
FIMP
FINAL DISPOSITION PROCESSED
01/08/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/03/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/03/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
10/03/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/18/2023
PUBO
PUBLISHED FOR OPPOSITION
07/18/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/28/2023
RFNT
REFUSAL PROCESSED BY IB
06/18/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/15/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/14/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/14/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/14/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/14/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/14/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/14/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/14/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/14/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/22/2023
RFRR
REFUSAL PROCESSED BY MPU
05/22/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/31/2023
CNRT
NON-FINAL ACTION WRITTEN
03/30/2023
DOCK
ASSIGNED TO EXAMINER
03/24/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
11/20/2022
MAFR
APPLICATION FILING RECEIPT MAILED
08/09/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/04/2022
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
08/03/2022
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
07/28/2022
Continuous trademark protection
Get notified about every new filing that threatens BARRIOLIDES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.